This study is conducted in Europe. The aim of this non-interventional study is to investigate the safety and effectiveness of insulin degludec (Tresiba®) in a real world population with type 1 (T1DM) and 2 (T2DM) diabetes mellitus.

Inclusion Criteria:

• Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)
• Male or female patients at least 18 years of age at time of informed consent
• T1DM (diagnosed clinically) prior to inclusion in the study, and/or T2DM, insulin using patients (diagnosed clinically) prior to inclusion in the study
• Planned initiation with Tresiba®

Exclusion Criteria:

• Known or suspected hypersensitivity to Tresiba® or any of the excipients listed in Section 6.1 of the SmPC (Summary of Product Characteristics) or related products
• Previous participation in this study (i.e. provision of informed consent)
• Patients who have previously been treated with Tresiba®
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Male or female patients aged at least 18 years of age with either T1DM or T2DM (insulin using) (clinically diagnosed) prior to visit 1, who signed an informed consent form, and whose physician plans to start Tresiba® treatment are eligible for entry in this study.

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com